SRD5A3

Across TCGA pan-cancer cohorts, SRD5A3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SRD5A3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SRD5A3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SRD5A3 is over-expressed in tumor.

CCRCC, LUAD, and HNSC are the cancer types where SRD5A3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRD5A3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.655	<.001	9	view →
LUAD	Female	II,III,IV	+1.039	<.001	8	view →
HNSC	Male	II,III,IV	+0.494	<.001	8	view →
LSCC	Male	All	+0.612	<.001	7	view →
COAD	Male	All	+0.359	.005	1	view →
PDAC	All	All	+0.347	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SRD5A3–CCRCC

Open the CCRCC breakdown →